56 Les biomarqueurs moléculaires en oncologie
43. Marks JL, Gong Y, Chitale D, et al. (2008) Novel MEK1 mutation identified by
l l
mutational analysis of epidermal growth factor receptor signaling pathway genes in lung
adenocarcinoma. Cancer Res 68: 5524-8
44. Chapman PB, Hauschild A, Robert C, et al. (2011) Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-16
45. Sosman JA, Kim KB, Schuchter L, et al. (2012) Survival in BRAF V600-mutant advanced
l l
melanoma treated with vemurafenib. N Engl J Med 366: 707-14
46. Hauschild A, Grob JJ, Demidov LV, et al. (2012) Dabrafenib in BRAF-mutated metastatic
l l
melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:
358-65
47. Long GV, Trefzer U, Davies MA, et al. (2012) Dabrafenib in patients with Val600Glu or
l l
Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre,
open-label, phase 2 trial. Lancet Oncol 13: 1087-95
48. Flaherty KT, Infante JR, Daud A, et al. (2012) Combined BRAF and MEK inhibition in
melanoma with BRAF V600 mutations. N Engl J Med 367: 1694-703
49. Flaherty KT, Robert C, Hersey P, et al. (2012) Improved survival with MEK inhibition in
l l
BRAF-mutated melanoma. N Engl J Med 367: 107-14
50. Carvajal RD, Antonescu CR, Wolchok JD, et al. (2011) KIT as a therapeutic target in
l l
metastatic melanoma. JAMA 305: 2327-34